Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing

Elizabeth J. Brown, Martin R. Pollak, Moumita Barua

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The haploid human genome is composed of three billion base pairs, about one percent of which consist of exonic regions, the coding sequence for functional proteins, also now known as the 'exome'. The development of next-generation sequencing makes it possible from a technical and economic standpoint to sequence an individual's exome but at the cost of generating long lists of gene variants that are not straightforward to interpret. Various public consortiums such as the 1000 Genomes Project and the NHLBI Exome Sequencing Project have sequenced the exomes and a subset of entire genomes of over 2500 control individuals with ongoing efforts to further catalog genetic variation in humans. 1 The use of these public databases facilitates the interpretation of these variant lists produced by exome sequencing and, as a result, novel genetic variants linked to the disease are being discovered and reported at a record rate. However, the interpretation of these results and their bearing on diagnosis, prognosis, and treatment is becoming even more complicated. Here, we discuss the application of genetic testing to individuals with focal and segmental glomerulosclerosis (FSGS), taking a historical perspective on gene identification and its clinical implications along with the growing potential of next-generation sequencing.

Original languageEnglish (US)
Pages (from-to)1030-1038
Number of pages9
JournalKidney International
Volume85
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Exome
Focal Segmental Glomerulosclerosis
Nephrotic Syndrome
Genetic Testing
Genome
National Heart, Lung, and Blood Institute (U.S.)
Haploidy
Human Genome
Base Pairing
Genes
Economics
Databases
Proteins

Keywords

  • Focal segmental glomerulosclerosis
  • Genetic renal disease
  • Nephritic syndrome

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. / Brown, Elizabeth J.; Pollak, Martin R.; Barua, Moumita.

In: Kidney International, Vol. 85, No. 5, 2014, p. 1030-1038.

Research output: Contribution to journalArticle

Brown, Elizabeth J. ; Pollak, Martin R. ; Barua, Moumita. / Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. In: Kidney International. 2014 ; Vol. 85, No. 5. pp. 1030-1038.
@article{20baeacb895c4178a336d17cbaf960a5,
title = "Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing",
abstract = "The haploid human genome is composed of three billion base pairs, about one percent of which consist of exonic regions, the coding sequence for functional proteins, also now known as the 'exome'. The development of next-generation sequencing makes it possible from a technical and economic standpoint to sequence an individual's exome but at the cost of generating long lists of gene variants that are not straightforward to interpret. Various public consortiums such as the 1000 Genomes Project and the NHLBI Exome Sequencing Project have sequenced the exomes and a subset of entire genomes of over 2500 control individuals with ongoing efforts to further catalog genetic variation in humans. 1 The use of these public databases facilitates the interpretation of these variant lists produced by exome sequencing and, as a result, novel genetic variants linked to the disease are being discovered and reported at a record rate. However, the interpretation of these results and their bearing on diagnosis, prognosis, and treatment is becoming even more complicated. Here, we discuss the application of genetic testing to individuals with focal and segmental glomerulosclerosis (FSGS), taking a historical perspective on gene identification and its clinical implications along with the growing potential of next-generation sequencing.",
keywords = "Focal segmental glomerulosclerosis, Genetic renal disease, Nephritic syndrome",
author = "Brown, {Elizabeth J.} and Pollak, {Martin R.} and Moumita Barua",
year = "2014",
doi = "10.1038/ki.2014.48",
language = "English (US)",
volume = "85",
pages = "1030--1038",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing

AU - Brown, Elizabeth J.

AU - Pollak, Martin R.

AU - Barua, Moumita

PY - 2014

Y1 - 2014

N2 - The haploid human genome is composed of three billion base pairs, about one percent of which consist of exonic regions, the coding sequence for functional proteins, also now known as the 'exome'. The development of next-generation sequencing makes it possible from a technical and economic standpoint to sequence an individual's exome but at the cost of generating long lists of gene variants that are not straightforward to interpret. Various public consortiums such as the 1000 Genomes Project and the NHLBI Exome Sequencing Project have sequenced the exomes and a subset of entire genomes of over 2500 control individuals with ongoing efforts to further catalog genetic variation in humans. 1 The use of these public databases facilitates the interpretation of these variant lists produced by exome sequencing and, as a result, novel genetic variants linked to the disease are being discovered and reported at a record rate. However, the interpretation of these results and their bearing on diagnosis, prognosis, and treatment is becoming even more complicated. Here, we discuss the application of genetic testing to individuals with focal and segmental glomerulosclerosis (FSGS), taking a historical perspective on gene identification and its clinical implications along with the growing potential of next-generation sequencing.

AB - The haploid human genome is composed of three billion base pairs, about one percent of which consist of exonic regions, the coding sequence for functional proteins, also now known as the 'exome'. The development of next-generation sequencing makes it possible from a technical and economic standpoint to sequence an individual's exome but at the cost of generating long lists of gene variants that are not straightforward to interpret. Various public consortiums such as the 1000 Genomes Project and the NHLBI Exome Sequencing Project have sequenced the exomes and a subset of entire genomes of over 2500 control individuals with ongoing efforts to further catalog genetic variation in humans. 1 The use of these public databases facilitates the interpretation of these variant lists produced by exome sequencing and, as a result, novel genetic variants linked to the disease are being discovered and reported at a record rate. However, the interpretation of these results and their bearing on diagnosis, prognosis, and treatment is becoming even more complicated. Here, we discuss the application of genetic testing to individuals with focal and segmental glomerulosclerosis (FSGS), taking a historical perspective on gene identification and its clinical implications along with the growing potential of next-generation sequencing.

KW - Focal segmental glomerulosclerosis

KW - Genetic renal disease

KW - Nephritic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84899943190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899943190&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.48

DO - 10.1038/ki.2014.48

M3 - Article

VL - 85

SP - 1030

EP - 1038

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -